Quigley Reports Results For Phase IIb Study Of QR-333
Quigley has reported the results from its phase IIb double-blind, placebo-controlled, study of topical compound QR-333. It is intended for the treatment of symptomatic diabetic peripheral neuropathy. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.